Medicare Enrolled
Dr. Yaser Homsi, M.D.
Hematology & Oncology · Huntington Beach, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Homsi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Homsi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Homsi
Dr. Yaser Homsi is a hematology & oncology specialist in Huntington Beach, CA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Homsi performed 18,829 Medicare services across 862 unique beneficiaries.
Between the years covered by Open Payments, Dr. Homsi received a total of $9,016 from 69 pharmaceutical and/or device companies across 387 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Homsi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 24% volume in CA
$9,016 industry payments
Medicare Practice Summary
Medicare Utilization ↗18,829
Medicare services
Top 24% in CA for hematology & oncology
862
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,108 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Romosozumab injection (Evenity) for osteoporosis | 10,500 | $8 | $35 |
| Denosumab injection (Prolia/Xgeva) | 4,320 | $18 | $81 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
1,410 | $36 | $161 |
| Anti-nausea injection (ondansetron/Zofran) | 596 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
426 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
205 | $96 | $481 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
194 | $12 | $81 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
158 | $14 | $93 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
149 | $58 | $269 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
145 | $18 | $88 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
131 | $120 | $606 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
106 | $64 | $341 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
70 | $7 | $35 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
48 | $12 | $69 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
43 | $29 | $220 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
39 | $26 | $147 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
39 | $148 | $672 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
39 | $1 | $6 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
36 | $1 | $4 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
34 | $110 | $461 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
34 | $1 | $21 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
29 | $59 | $295 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
25 | $31 | $134 |
| New patient office visit, complex (60-74 min) | 21 | $152 | $571 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
19 | $109 | $408 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
13 | $89 | $422 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.3% high complexity
86.9% medium
2.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,016
Total received (2018-2024)
Avg $1,288/year across 7 years
Top 33% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
387
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,224 (80.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,479 (16.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$313 (3.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,524
2023
$267
2022
$87
2021
$1,162
2020
$1,776
2019
$2,602
2018
$1,598
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Daiichi Sankyo Inc.
$1,479
ABBVIE INC.
$23
Rigel Pharmaceuticals, Inc.
$22
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Daiichi Sankyo Inc.
$1,549
E.R. Squibb & Sons, L.L.C.
$553
Novartis Pharmaceuticals Corporation
$452
AstraZeneca Pharmaceuticals LP
$451
PFIZER INC.
$433
Merck Sharp & Dohme Corporation
$329
Celgene Corporation
$307
Janssen Biotech, Inc.
$294
Pharmacyclics LLC, An AbbVie Company
$289
Exelixis Inc.
$275
Amgen Inc.
$263
Bayer HealthCare Pharmaceuticals Inc.
$260
Astellas Pharma US Inc
$243
Incyte Corporation
$232
Takeda Pharmaceuticals U.S.A., Inc.
$198
Teva Pharmaceuticals USA, Inc.
$189
GENZYME CORPORATION
$188
Regeneron Healthcare Solutions, Inc.
$149
Genentech USA, Inc.
$142
Boehringer Ingelheim Pharmaceuticals, Inc.
$112
AbbVie Inc.
$103
Puma Biotechnology, Inc.
$102
SANOFI-AVENTIS U.S. LLC
$100
Rigel Pharmaceuticals, Inc.
$97
Alexion Pharmaceuticals, Inc.
$95
BeiGene USA, Inc.
$91
Blueprint Medicines Corporation
$81
Lexicon Pharmaceuticals, Inc.
$78
BIOTRONIK INC.
$69
EMD Serono, Inc.
$67
TerSera Therapeutics LLC
$58
Ipsen Biopharmaceuticals, Inc
$57
Karyopharm Therapeutics Inc.
$54
Merck Sharp & Dohme LLC
$50
Verastem, Inc.
$49
Octapharma USA, Inc.
$48
Gilead Sciences, Inc.
$46
Seagen Inc.
$45
AMAG Pharmaceuticals, Inc.
$44
AbbVie, Inc.
$44
Dendreon Pharmaceuticals LLC
$42
Array BioPharma Inc.
$42
Agios Pharmaceuticals, Inc.
$41
Baxter Healthcare
$38
EUSA Pharma (US) LLC
$37
Stemline Therapeutics Inc.
$35
Eisai Inc.
$34
Kite Pharma, Inc.
$33
Janssen Scientific Affairs, LLC
$29
Secura Bio, Inc.
$28
Jazz Pharmaceuticals Inc.
$24
INSYS Therapeutics Inc
$23
ABBVIE INC.
$23
Seattle Genetics, Inc.
$22
Taiho Oncology, Inc.
$22
Aurobindo Pharma USA, Inc.
$21
Bayer Healthcare Pharmaceuticals Inc.
$20
Spectrum Pharmaceuticals Inc.
$20
Coherus Biosciences Inc.
$20
CSL Behring
$20
EISAI INC.
$20
Helsinn Therapeutics (U.S.), Inc.
$20
Horizon Therapeutics plc
$20
Dova Pharmaceuticals
$19
Lilly USA, LLC
$18
Sun Pharmaceutical Industries Inc.
$16
Myovant Sciences Inc.
$15
Mylan Institutional Inc.
$15
Advanced Accelerator Applications
$12
Top 3 companies account for 28.3% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Afstyla · Alecensa · Aliqopa · Avastin · BENDEKA · BIOMONITOR · BOSULIF · BRUKINSA · BYNFEZIA PEN · Bavencio · Beleodaq · Braftovi · CALQUENCE · Cabometyx · Copiktra · DARZALEX · Doptelet · ELITEK · EMPLICITI · EPKINLY · ERLEADA · Enhertu · Erleada · FARYDAK · FERAHEME · Folotyn · Fulphila · GAVRETO · GAZYVA · GILOTRIF · GRANIX · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRYSTEXXA · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MONJUVI · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Nexavar · ONUREG · OPDIVO · ORGOVYX · Orserdu · PADCEV · PROMACTA · PROVENGE · Perjeta · Pomalyst · REBLOZYL · RYDAPT · Revlimid · Rezlidhia · SANDOSTATIN · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYNDROS · Stivarga · Sylvant · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · TISSEEL · Tavalisse · ULTOMIRIS · Udenyca · Ultomiris · VALCHLOR · VENCLEXTA · VOTRIENT · Venclexta · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XOSPATA · XPOVIO · XTANDI · Xermelo · Xospata · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (80%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
204
Per 100K population
6.4
County median income
$113,702
Nearest hospital
HUNTINGTON BEACH HOSPITAL
3.1 mi
3.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Homsi is a mixed practice specialist, with above-average Medicare volume (top 24% in CA), with low-engagement industry engagement, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Homsi experienced with romosozumab injection (evenity) for osteoporosis?
Based on Medicare claims data, Dr. Homsi performed 10,500 romosozumab injection (evenity) for osteoporosis services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Homsi receive payments from pharmaceutical companies?
Yes. Dr. Homsi received a total of $9,016 from 69 companies across 387 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Homsi's costs compare to other hematology & oncology specialists in Huntington Beach?
Dr. Homsi's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Homsi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Huntington Beach
Browse hematology & oncology specialists in Huntington Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology